Skip to content
Screener

Biodesix, Inc. BDSX Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$20.0MBeat by $1.6M
EPS-$1.60Miss by $0.20
Revenue estimate$18.5M
EPS estimate-$1.40

Next report

Nov 5, 2026 (In 3 days)
Revenue estimate$27.5M
EPS estimate-$0.75

Financials

Q2 2025

Income statement

See full
Revenue$20.0M+11.7%
Operating income-$9.7M-18.0%
Net income-$11.5M-6.1%
EPS (diluted)-$1.56-1,850%

Balance sheet

See full
Cash & equivalents$20.7M-50.9%
Total debt$72.1M+17.1%
Total equity$1.1M-96.9%
Total assets$87.7M-24.3%

Cash flow

See full
Operating cash flow-$6.6M+64.6%
CapEx$51.0K-97.4%
Free cash flow-$6.6M+67.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$40.33M-79.3%
Enterprise value$91.73M-57.1%
P/S0.5×-2.7×

Profitability

See full
Operating margin-44.5%-7.0pp
Net margin-53.7%-11.3pp
FCF margin-40.7%-15.2pp

Returns & leverage

See full
Return on equity-219.7%—
Debt / equity63.4×+61.7×
Current ratio2.1×-1.1×

Segments

By product

See full
Diagnostic Tests$17.9M+8.2%
Development Services$2.1M+53.0%

FAQ

When did Biodesix, Inc. report Q2 2025 earnings?
Biodesix, Inc. (BDSX) reported Q2 2025 earnings on August 7, 2025 after market close.
What were Biodesix, Inc.'s Q2 2025 revenue and EPS?
Biodesix, Inc. reported revenue of $20.0M and eps of $-1.60 for Q2 2025.
Did Biodesix, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $18.5M by $1.6M. EPS missed the consensus estimate of $-1.40 by $0.20.
How did Biodesix, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.7% from $17.9M a year earlier and eps declined 1900.0% from $-0.08.
Where can I find Biodesix, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001439725-25-000003) and the 10-Q periodic report (0000950170-25-105026) directly on SEC EDGAR. The filing index links above go to sec.gov.